Precision Medicine

The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.

We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:

  • Will testing change patient management for this indication?
  • If so, what tests and/or therapies should I use?
  • Should we cover testing and/or therapies?
  • Can we manage these services internally?

 

 

Genetic Testing to Predict Allopurinol Toxicity

This report examines the clinical utility of genetic testing of the HLA-B*58:01 variant in patients needing treatment with allopurinol to reduce the production of uric acid. The evidence for the use of genetic testing is evaluated with respect to changing allopurinol dose or changing to another drug in ord…

EndoPredict (Myriad Genetics)

Breast cancer is the most common cancer in American women, with 1 in 8 women developing breast cancer during their lifetime in the United States. It is 1 of the most common forms of cancer, representing 14.6% of all new cancer cases in the United States, with an estimated 246,660 new cases of breast cancer diagno…

The Prostate Health Index for Prebiopsy Triage (Beckman Coulter)

In the United States, prostate cancer is the second most commonly diagnosed cancer (after skin cancers) and the third most common cause of cancer-related deaths in men. Approximately 1 in 7 men will be diagnosed with prostate cancer in his lifetime. It is estimated that 161,360 men will be diagnosed with prostate…

Fecal Calprotectin Assay for Monitoring Disease Activity in Crohn Disease

Purpose of Technology: Mucosal healing is emerging as a primary therapeutic target for Crohn disease (CD), as a growing body of evidence suggests that it is associated with better patient outcomes. The definitive standard for assessing intestinal inflammation is ileocolonoscopy; however, this technique is invasive, time-cons…

Fecal Calprotectin Assay for Monitoring Postoperative Recurrence of Crohn Disease

Purpose of Technology: Crohn disease (CD) patients require frequent monitoring after intestinal resection due to a high likelihood of postoperative recurrence. The reference standard for assessing endoscopic recurrence after ileocolonic resection is ileocolonoscopy; however, this technique is invasive, time consuming, expens…

Pharmacogenomic Testing for Selected Psychiatric and Behavioral Conditions

This report examines the clinical utility of pharmacogenomic testing to inform the selection or dose of medications for individuals diagnosed with depression, mood disorders, psychosis, anxiety, attention-deficit/hyperactivity disorder, or substance use disorder. First, evidence is evaluated to determine whether …

Genetic Testing for Fragile X−Associated Tremor/Ataxia Syndrome (FXTAS)

This report evaluates the clinical utility of genetic testing for fragile X−associated tremor/ataxia syndrome (FXTAS). The goal of this report is to assess how genetic testing of men and women with clinical and/or radiologic features suggestive of FXTAS changes patient outcomes, alters diagnostic thinking, results in decision-making guidance, and/or leads to familial and societal impacts.

MTHFR Pharmacogenetic Genotyping for Altering Drug Treatment

This report evaluates the clinical utility for MTHFR pharmacogenomic genotyping in pediatric or adult patients to alter drug choice, drug dose, or otherwise mitigate drug treatment according to patient genotype in order to avoid adverse events, maintain adherence, and improve disease outcomes.

Genetic Testing for Fragile X-Associated Primary Ovarian Insufficiency (FXPOI)

This report evaluates the clinical utility of genetic testing for fragile X-associated primary ovarian insufficiency (FXPOI). The goal of this report is to assess how genetic testing of women with primary ovarian insufficiency (POI) to diagnose FXPOI changes patient outcomes, alters diagnostic thinking, resu…

GeneSight Psychotropic (Assurex Health Inc.)

Prescription drug use in the United States has steadily increased. Following this trend, pharmacotherapy for the treatment of neuropsychiatric disorders has also increased over the past several decades. According to a 2012 national survey, antidepressants were the third most commonly mentioned drug by therapeutic category at office visits. The benefit of prescription drug use has bee…